A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non ‐small cell lung cancer harboring EGFR mutations (JMTO LC12‐01)

ConclusionsPatients on G and Pem or Doc beyond PD showed a longer PFS than those on single-agent chemotherapy; however, it was associated with increased toxicity.

Source: Thoracic Cancer - May 14, 2022 Category: Cancer & Oncology Authors: Kazuhiro Asami, Masahiko Ando, Takashi Nishimura, Takashi Yokoi, Atsuhisa Tamura, Koichi Minato, Masahide Mori, Fumitaka Ogushi, Akiyoshi Yamamoto, Hiroshige Yoshioka, Masaaki Kawahara, Shinji Atagi Tags: ORIGINAL ARTICLE Source Type: research